CN105726702A - Preparation for treating chronic diabetic foot ulcers and preparation method and application thereof - Google Patents
Preparation for treating chronic diabetic foot ulcers and preparation method and application thereof Download PDFInfo
- Publication number
- CN105726702A CN105726702A CN201610235298.3A CN201610235298A CN105726702A CN 105726702 A CN105726702 A CN 105726702A CN 201610235298 A CN201610235298 A CN 201610235298A CN 105726702 A CN105726702 A CN 105726702A
- Authority
- CN
- China
- Prior art keywords
- preparation
- diabetic foot
- parts
- rhizoma
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 43
- 208000008960 Diabetic foot Diseases 0.000 title claims abstract description 28
- 230000001684 chronic effect Effects 0.000 title claims abstract description 23
- 238000011282 treatment Methods 0.000 claims abstract description 26
- 239000000203 mixture Substances 0.000 claims abstract description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000000843 powder Substances 0.000 claims abstract description 14
- 239000002994 raw material Substances 0.000 claims abstract description 14
- 239000000706 filtrate Substances 0.000 claims abstract description 12
- 239000008367 deionised water Substances 0.000 claims abstract description 6
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 6
- 235000021419 vinegar Nutrition 0.000 claims abstract description 6
- 239000000052 vinegar Substances 0.000 claims abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 6
- 208000025865 Ulcer Diseases 0.000 claims description 32
- 231100000397 ulcer Toxicity 0.000 claims description 32
- 239000003814 drug Substances 0.000 claims description 24
- 241000282472 Canis lupus familiaris Species 0.000 claims description 17
- 244000025254 Cannabis sativa Species 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 13
- 230000008569 process Effects 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 5
- 238000002386 leaching Methods 0.000 claims description 5
- 230000001737 promoting effect Effects 0.000 abstract description 17
- 230000029663 wound healing Effects 0.000 abstract description 14
- 239000008280 blood Substances 0.000 abstract description 10
- 210000004369 blood Anatomy 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 9
- 230000017531 blood circulation Effects 0.000 abstract description 5
- 230000036407 pain Effects 0.000 abstract description 5
- 239000000243 solution Substances 0.000 abstract description 5
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 231100000419 toxicity Toxicity 0.000 abstract description 3
- 230000001988 toxicity Effects 0.000 abstract description 3
- 230000004087 circulation Effects 0.000 abstract description 2
- 238000010792 warming Methods 0.000 abstract description 2
- 240000004500 Alysicarpus vaginalis Species 0.000 abstract 2
- 241001101998 Galium Species 0.000 abstract 2
- 235000014820 Galium aparine Nutrition 0.000 abstract 2
- 241000768957 Primulina fimbrisepala Species 0.000 abstract 2
- 241000612118 Samolus valerandi Species 0.000 abstract 2
- 241000894006 Bacteria Species 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 230000003467 diminishing effect Effects 0.000 abstract 1
- 230000012010 growth Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000011259 mixed solution Substances 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 230000017423 tissue regeneration Effects 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 description 35
- 206010052428 Wound Diseases 0.000 description 34
- 229940079593 drug Drugs 0.000 description 12
- 230000035876 healing Effects 0.000 description 12
- 241000700199 Cavia porcellus Species 0.000 description 10
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000005469 granulation Methods 0.000 description 7
- 230000003179 granulation Effects 0.000 description 7
- 206010028851 Necrosis Diseases 0.000 description 6
- 206010040943 Skin Ulcer Diseases 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000017074 necrotic cell death Effects 0.000 description 6
- 239000011505 plaster Substances 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 231100000019 skin ulcer Toxicity 0.000 description 6
- 229940099259 vaseline Drugs 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 230000002951 depilatory effect Effects 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 231100000614 poison Toxicity 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 239000003440 toxic substance Substances 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 239000002390 adhesive tape Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000035617 depilation Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- QTQGHKVYLQBJLO-UHFFFAOYSA-N 4-methylbenzenesulfonate;(4-methyl-1-oxo-1-phenylmethoxypentan-2-yl)azanium Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.CC(C)CC(N)C(=O)OCC1=CC=CC=C1 QTQGHKVYLQBJLO-UHFFFAOYSA-N 0.000 description 2
- 206010059245 Angiopathy Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 240000001624 Espostoa lanata Species 0.000 description 2
- 235000009161 Espostoa lanata Nutrition 0.000 description 2
- 206010017553 Furuncle Diseases 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- 206010020565 Hyperaemia Diseases 0.000 description 2
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 238000002266 amputation Methods 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- FCPVYOBCFFNJFS-LQDWTQKMSA-M benzylpenicillin sodium Chemical compound [Na+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 FCPVYOBCFFNJFS-LQDWTQKMSA-M 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000001804 debridement Methods 0.000 description 2
- 230000000249 desinfective effect Effects 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000003118 histopathologic effect Effects 0.000 description 2
- 229960001401 hydrocortisone sodium succinate Drugs 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 229960000282 metronidazole Drugs 0.000 description 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 230000037311 normal skin Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 206010034754 petechiae Diseases 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- WTQYWNWRJNXDEG-UHFFFAOYSA-N 6-Hydroxy-hyoscyamin Natural products CN1C(C2)CC(O)C1CC2OC(=O)C(CO)C1=CC=CC=C1 WTQYWNWRJNXDEG-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 241000202567 Fatsia japonica Species 0.000 description 1
- 208000014770 Foot disease Diseases 0.000 description 1
- 208000036119 Frailty Diseases 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000015817 Infant Nutrition disease Diseases 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 208000005268 Neurogenic Arthropathy Diseases 0.000 description 1
- 206010029326 Neuropathic arthropathy Diseases 0.000 description 1
- 206010034038 Parotitis Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 244000179560 Prunella vulgaris Species 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 208000031320 Teratogenesis Diseases 0.000 description 1
- CBWUNQZJGJFJLZ-UHFFFAOYSA-N [Cl].Cl Chemical compound [Cl].Cl CBWUNQZJGJFJLZ-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- -1 amine ketone Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- WTQYWNWRJNXDEG-LEOABGAYSA-N anisodamine Chemical compound C1([C@@H](CO)C(=O)O[C@@H]2C[C@H]3[C@@H](O)C[C@@H](C2)N3C)=CC=CC=C1 WTQYWNWRJNXDEG-LEOABGAYSA-N 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000001741 anti-phlogistic effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960002233 benzalkonium bromide Drugs 0.000 description 1
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 description 1
- IISBACLAFKSPIT-UHFFFAOYSA-N bisphenol A Chemical compound C=1C=C(O)C=CC=1C(C)(C)C1=CC=C(O)C=C1 IISBACLAFKSPIT-UHFFFAOYSA-N 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960004588 cilostazol Drugs 0.000 description 1
- RRGUKTPIGVIEKM-UHFFFAOYSA-N cilostazol Chemical compound C=1C=C2NC(=O)CCC2=CC=1OCCCCC1=NN=NN1C1CCCCC1 RRGUKTPIGVIEKM-UHFFFAOYSA-N 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229960002768 dipyridamole Drugs 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- CHNUOJQWGUIOLD-NFZZJPOKSA-N epalrestat Chemical compound C=1C=CC=CC=1\C=C(/C)\C=C1/SC(=S)N(CC(O)=O)C1=O CHNUOJQWGUIOLD-NFZZJPOKSA-N 0.000 description 1
- 229950010170 epalrestat Drugs 0.000 description 1
- CHNUOJQWGUIOLD-UHFFFAOYSA-N epalrestate Natural products C=1C=CC=CC=1C=C(C)C=C1SC(=S)N(CC(O)=O)C1=O CHNUOJQWGUIOLD-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008899 fufang danshen Substances 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 229940116314 ketaject Drugs 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000003265 lymphadenitis Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- IAIWVQXQOWNYOU-FPYGCLRLSA-N nitrofural Chemical compound NC(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 IAIWVQXQOWNYOU-FPYGCLRLSA-N 0.000 description 1
- 229960000349 nitrofural Drugs 0.000 description 1
- 229940127017 oral antidiabetic Drugs 0.000 description 1
- 239000003538 oral antidiabetic agent Substances 0.000 description 1
- 229940125395 oral insulin Drugs 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 239000003860 topical agent Substances 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a preparation for treating chronic diabetic foot ulcers and a preparation method and application thereof.The preparation is prepared from, by weight, 10-18 parts of herb of alysicarpus vaginalis, 22-30 parts of rhizomes of chirita fimbrisepala, 15-23 parts of herb of bunge bedstraw and 2-8 parts of common dysosmatis rhizomes and roots.Herb of alysicarpus vaginalis and rhizomes of chirita fimbrisepala are smashed, sieved, added with a 75% ethanol solution, treated at high temperature and high pressure and filtered to obtain filtrate, and then a mixed solution A is prepared; herb of bunge bedstraw is smashed, sieved, heated by adding deionized water and filtered to obtain filtrate, and then a mixture B is prepared; common dysosmatis rhizomes and roots are smashed, sieved, stir-fried by adding table vinegar, ground and sieved, and then common dysosmatis rhizome and root powder is prepared; the mixture A and the mixture B are mixed, heated, stirred and then added with the common dysosmatis rhizome and root powder, the mixture is heated, stirred and cooled to room temperature, and then the preparation is prepared.According to the preparation, the effects of clearing heat, removing toxicity, removing slough, promoting growth of tissue regeneration, promoting blood circulation, removing blood stasis, warming and activating the meridians, promoting qi circulation, easing pain, killing bacteria and diminishing inflammations are achieved through the synergistic effect of all the raw materials; when the preparation is used for treating the chronic diabetic foot ulcers, the treatment effect is obvious, the wound healing effect is good, no toxic or side effect is generated, and the chronic diabetic foot ulcers do not relapse after being cured.
Description
Technical field
The present invention relates to pharmaceutical technology field, a kind of preparation treating diabetic foot chronic ulcer and preparation method thereof and
Application.
Background technology
Foot is a complicated target organ of this multisystem disease of diabetes.Diabetics is because peripheral neuropathy is with outer
The mechanical pressure that week angiopathy merging is too high, can cause foot soft tissue and the destruction of osteoarticular system and teratogenesis, enter
And cause a series of foot problems, close from slight nervous symptoms to serious ulcer, infection, angiopathy, Charcot
Joint is sick and Neuropathic is fractured.If active treatment can not fully solve symptom and the complication that lower limb occur, then can cause
Catastrophic consequence.
The drug main being presently used for treating diabetic foot to have: 1, improves Microcirculation for Treatment, mainly has Anisodamine, front
Row element E1, Chinese medicine preparation FUFANG DANSHEN ZHUSHEYE etc.；2, reduce blood coagulability, mainly have persantin, aspirin,
Warfarin, Cilostazol etc.；3, anti-infective therapy, main application broad ectrum antibiotic and metronidazole etc.；4, neuropathy medicine is improved
Thing, such as Epalrestat etc..Said medicine can only assist treatment diabetic foot, it is impossible to takes stopgap measures, and side effect is big, easily causes it
His complication.
Summary of the invention
It is an object of the invention to provide a kind for the treatment of both the principal and secondary aspects of a disease, the treatment diabetic foot of the difficulty in relapse after healing that has no side effect, controls
Preparation of chronic ulcer and its preparation method and application, with the problem solving to propose in above-mentioned background technology.
For achieving the above object, the present invention provides following technical scheme:
A kind of preparation treating diabetic foot chronic ulcer, is made up of according to the raw material of weight portion following: Canis familiaris L. ant grass 10-18 part,
Rhizoma Chiritae Fimbrisepalae 22-30 part, Herba Galii Bungei 15-23 part, Radix et Rhizoma Dysosmatis 2-8 part.
As the further scheme of the present invention: the preparation of described treatment diabetic foot chronic ulcer, by following according to weight portion
Raw material forms: Canis familiaris L. ant grass 12-16 part, Rhizoma Chiritae Fimbrisepalae 24-28 part, Herba Galii Bungei 17-21 part, Radix et Rhizoma Dysosmatis 4-6 part.
As the further scheme of the present invention: the preparation of described treatment diabetic foot chronic ulcer, by following according to weight portion
Raw material forms: Canis familiaris L. ant grass 14 parts, Rhizoma Chiritae Fimbrisepalae 26 parts, Herba Galii Bungei 19 parts, Radix et Rhizoma Dysosmatis 5 parts.
The preparation method of the preparation of described treatment diabetic foot chronic ulcer, comprises the steps of:
1) Canis familiaris L. ant grass, Rhizoma Chiritae Fimbrisepalae are pulverized 100-150 mesh sieve, add 75% ethanol solution of the two quality 8-10 times,
Under the High Temperature High Pressure of 4-5MPa, 100-120 DEG C, process 1-1.3h, take filtrate after filtration and prepare mixed liquor A；
2) Herba Galii Bungei pulverized, cross 200 mesh sieves, add the deionized water of its quality 13-15 times, add at 110-115 DEG C
Hot 1.5-2h, crosses leaching filtrate, prepares mixture B；
3) Radix et Rhizoma Dysosmatis was pulverized 60 mesh sieves, and added and fry at the vinegar of its quality 0.5-0.8 times, then 75-80 DEG C
15-20min processed, more ground 200 mesh sieves, prepare Radix et Rhizoma Dysosmatis powder；
4) mixture A is mixed with mixture B, then heated and stirred 15-20min at 140-150 DEG C, then it is down to 70-75
DEG C, add anistree Nelumbo nucifera Gaertn. Powder art, heated and stirred 30-35min at such a temperature, be down to room temperature and i.e. obtain preparation.
The application in preparation treatment diabetic foot chronic ulcer medicine of the described preparation.
Canis familiaris L. ant grass promoting blood circulation to remove obstruction in the collateral, clearing away heat and eliminating dampness in the present invention, refute atrophic debility of bones and swell, removing the necrotic tissue and promoting granulation.
Rhizoma Chiritae Fimbrisepalae strengthening the spleen to promote digestion, clearing away heat-damp and promoting diuresis, promoting blood circulation and stopping pain.For infantile malnutrition, stomachache, hepatitis, dysentery, pulmonary tuberculosis
Spitting of blood；It is hemorrhage that knife injury is controlled in external, innominate toxic swelling, traumatic injury.
Herba Galii Bungei cures mainly heat-clearing and toxic substances removing, relieving cough and asthma.For cough due to pathogenic wind-heat, pharyngitis, tonsillitis, feeling of fullness pain in stomach；
Eczema, furuncle, hemorrhoid are controlled in external.All herbal medicine, has heat-clearing and toxic substances removing, the effectiveness of Sweeling-eliminating medicine powder disease, can control snakeworm insect bite, also
Hematuria, urinary tract infection, icterohepatitis etc. can be controlled.
Radix et Rhizoma Dysosmatis has heat-clearing and toxic substances removing, effect of promoting blood circulation to remove blood stasis.It is usually used in venom, traumatic injury；External is controlled worm Serpentis and is stung
Wound, furuncle carbuncle, lymphadenitis, parotitis, breast carcinoma.
Compared with prior art, the invention has the beneficial effects as follows:
The present invention each raw material jointly act on heat-clearing and toxic substances removing, putrefaction-removing granulation-promoting, blood circulation promoting and blood stasis dispelling, promoting the flow of QI in the collateral by warming the meridian, circulation of qi promoting analgesia,
Bactericidal antiphlogistic, is conducive to improving the resistance of human body self, immunocompetence, and raw material is easy to get and low cost, is used for treating glycosuria
Foot disease chronic ulcer, therapeutic effect is obvious, and wound healing is effective, treating both the principal and secondary aspects of a disease, and has no side effect, and is difficult to after healing
Recurrence, it is to avoid side effect that diabetes treatment by western medicine foot produces and the great pain that amputation brings.
Detailed description of the invention
Below in conjunction with the embodiment of the present invention, the technical scheme in the embodiment of the present invention is clearly and completely described, aobvious
So, described embodiment is only a part of embodiment of the present invention rather than whole embodiments.Based in the present invention
Embodiment, the every other embodiment that those of ordinary skill in the art are obtained under not making creative work premise, all
Belong to the scope of protection of the invention.
Embodiment 1
In the embodiment of the present invention, a kind of preparation treating diabetic foot chronic ulcer, it is made up of according to the raw material of weight portion following:
Canis familiaris L. ant grass 10 parts, Rhizoma Chiritae Fimbrisepalae 22 parts, Herba Galii Bungei 15 parts, Radix et Rhizoma Dysosmatis 2 parts.
Canis familiaris L. ant grass, Rhizoma Chiritae Fimbrisepalae are pulverized 100 mesh sieves, add the ethanol solution that volumetric concentration is 75% of the two quality 80 times,
Under 4MPa, the High Temperature High Pressure of 100 DEG C, process 1h, take filtrate after filtration and prepare mixed liquor A.Herba Galii Bungei is pulverized, crosses 200
Mesh sieve, adds the deionized water of its quality 13 times, heats 1.5h, crosses leaching filtrate, prepare mixture B at 110 DEG C.
Radix et Rhizoma Dysosmatis was pulverized 60 mesh sieves, adds the vinegar of its quality 0.5 times, then at 75 DEG C, carry out parch 15min, then grind
Honed 200 mesh sieves, prepare Radix et Rhizoma Dysosmatis powder.Mixture A is mixed with mixture B, then heated and stirred 15min at 140 DEG C,
It is down to 70 DEG C again, adds Radix et Rhizoma Dysosmatis powder, at such a temperature heated and stirred 30min, be down to room temperature and i.e. obtain preparation.
Embodiment 2
In the embodiment of the present invention, a kind of preparation treating diabetic foot chronic ulcer, it is made up of according to the raw material of weight portion following:
Canis familiaris L. ant grass 18 parts, Rhizoma Chiritae Fimbrisepalae 30 parts, Herba Galii Bungei 23 parts, Radix et Rhizoma Dysosmatis 8 parts.
Canis familiaris L. ant grass, Rhizoma Chiritae Fimbrisepalae were pulverized 150 mesh sieves, added 75% ethanol solution of the two quality 10 times, 5MPa,
Process 1-1.3h under the High Temperature High Pressure of 100-120 DEG C, take filtrate after filtration and prepare mixed liquor A.Herba Galii Bungei is pulverized, crosses 200
Mesh sieve, adds the deionized water of its quality 15 times, heats 2h, crosses leaching filtrate, prepare mixture B at 115 DEG C.Will
Radix et Rhizoma Dysosmatis pulverized 60 mesh sieves, adds the vinegar of its quality 0.8 times, then carries out parch 20min at 80 DEG C, then grinds
Cross 200 mesh sieves, prepare Radix et Rhizoma Dysosmatis powder.Mixture A is mixed with mixture B, then heated and stirred 20min at 150 DEG C,
It is down to 75 DEG C again, adds Radix et Rhizoma Dysosmatis powder, at such a temperature heated and stirred 35min, be down to room temperature and i.e. obtain preparation.
Embodiment 3
In the embodiment of the present invention, a kind of preparation treating diabetic foot chronic ulcer, it is made up of according to the raw material of weight portion following:
Canis familiaris L. ant grass 12 parts, Rhizoma Chiritae Fimbrisepalae 24 parts, Herba Galii Bungei 17 parts, Radix et Rhizoma Dysosmatis 4 parts.
Canis familiaris L. ant grass, Rhizoma Chiritae Fimbrisepalae were pulverized 150 mesh sieves, added 75% ethanol solution of the two quality 9 times, 4.5MPa,
Process 1.3h under the High Temperature High Pressure of 110 DEG C, take filtrate after filtration and prepare mixed liquor A.Herba Galii Bungei is pulverized, crosses 200 mesh sieves,
Add the deionized water of its quality 14 times, at 114 DEG C, heat 2h, cross leaching filtrate, prepare mixture B.By Radix et Rhizoma Dysosmatis
Pulverized 60 mesh sieves, and added the vinegar of its quality 0.7 times, then at 78 DEG C, carry out parch 20min, more ground 200
Mesh sieve, prepares Radix et Rhizoma Dysosmatis powder.Mixture A is mixed with mixture B, then heated and stirred 20min at 145 DEG C, then
It is down to 75 DEG C, adds Radix et Rhizoma Dysosmatis powder, at such a temperature heated and stirred 33min, be down to room temperature and i.e. obtain preparation.
Embodiment 4
In the embodiment of the present invention, a kind of preparation treating diabetic foot chronic ulcer, it is made up of according to the raw material of weight portion following:
Canis familiaris L. ant grass 16 parts, Rhizoma Chiritae Fimbrisepalae 28 parts, Herba Galii Bungei 21 parts, Radix et Rhizoma Dysosmatis 6 parts.
Preparation process is consistent with embodiment 3.
Embodiment 5
In the embodiment of the present invention, a kind of preparation treating diabetic foot chronic ulcer, it is made up of according to the raw material of weight portion following:
Canis familiaris L. ant grass 14 parts, Rhizoma Chiritae Fimbrisepalae 26 parts, Herba Galii Bungei 19 parts, Radix et Rhizoma Dysosmatis 5 parts.
Preparation process is consistent with embodiment 3.
Comparative example 1
In addition to not containing Rhizoma Chiritae Fimbrisepalae, its formula and preparation process are consistent with embodiment 5.
Comparative example 2
Containing only Rhizoma Chiritae Fimbrisepalae, its preparation process is consistent with embodiment 5.
Using method is: first skin ulcer face is first carried out with 3% hydrogen peroxide, wipes out slough, then cleans with normal saline,
Surrounding skin 75% alcohol disinfecting, then applies the present invention on skin ulcer face equably, to cover and to exceed whole skin ulcer face to week
Enclosing normal skin, then cover 2～3 layers of sterile gauze, fix with Breathable adhesive tape, change dressings 1 day 1 time, treating 20 days is 1
The individual course for the treatment of.
Embodiment 6 acute toxicity testing data
1, experimental technique
Depilatory is uniformly coated with by guinea pig back spinal column both sides, makes unhairing scope about 20 square centimeters.Clean depilatory is returned
Cage is observed 24 hours, and often group Cavia porcellus is coated with 4g, 8g and 12g of the present invention respectively, and another group is coated with the every twice-daily of solvent 0.8ml,
Continuous one week, after experiment terminates, being put to death by Cavia porcellus, the heart, liver, kidney and depilation skin do pathological examination.
2, result
Above-mentioned three groups of medication Cavia porcellus trunks depilation district, has no that local skin has edema, hyperemia, erythema, petechia and ulcer.
Medication group Cavia porcellus chroma of hair, ingest, the matched group no significant difference such as extremity are movable, histopathologic examination, the administration group heart,
Liver, kidney and depilation skin compare also no significant difference with compareing word.
Result is pointed out, and the present invention, without local irritant effect, also has no that general toxicity shows.Show that the present invention uses safety.
Embodiment 7 long term toxicity test data
1, experimental technique
Cavia porcellus is randomly divided into 4 groups, often group 15.In guinea pig back spinal column both sides, depilatory is uniformly coated with so that it is de-
Hair scope about 20 square centimeters.Clean depilatory, often organize Cavia porcellus after observing 24 hours and be coated with 0.2g, 0.4g of the present invention respectively
And 0.8g, another group is coated with the every twice-daily of solvent 0.8ml, continuous 30 days, observes the ordinary circumstance of Cavia porcellus, after experiment terminates
Put to death animal and carry out hematology, blood biochemical and pathological examination.
2, result
Above-mentioned three groups of medication Cavia porcellus trunks go to hair-fields, have no that local skin has edema, hyperemia, erythema, petechia and ulcer.
Medication group and control animals chroma of hair, ingest, matched group no significant difference, the blood biochemistry checking such as extremity are movable, use
Medicine group and matched group are all in normal range.Histopathologic examination, tests each group of heart, liver, kidney and local skin and is showed no bright
Aobvious pathological changes.Prompting, long-term prescription of the present invention is showed no obvious toxic action to local skin and whole body important organ.Test
Result shows；Experiment safety of the present invention.
Embodiment 8 pharmacodynamic experiment
Its impact on the healing of rat refractory wound surface of this laboratory observation.
1 materials and methods
1.1 animals: cleaning grade SD rat 40, male, weight 200-250g, average (220.32 ± 10.10) g is (by mountain
University students's system breeding center, east provides).
1.2 medicines: vaseline, necrosis removing and granulation promoting plaster, the embodiment of the present invention 5.
1.3 reagent and instrument: ketaject injection (every 011g/2mL, Hengrui Medicine Co., Ltd., Jiangsu Prov. produces,
Lot number: KH051001)；Hydrocortisone sodium succinate (every 50mg/2mL, Tianjin Biochemical Pharmaceutical Factory produces, batch
Number: 20010419,20060104)；Benzylpenicillin sodium for injection (800,000 U/ prop up, and Huabei Pharmaceutic Co., Ltd produces, batch
Number: Y0511222).Electrocardiograph paper (specification 50mm × 30m, Shanghai three or five company limited of paper plant produces).
1.4 modeling methods: full thickness dermal method makes animal body surface Ulcer Models.Rat is randomly divided into 5 groups: general wound surface
Group, model control group, vaseline group, necrosis removing and granulation promoting plaster group, of the present invention group, often group 8.Rats by intraperitoneal injection hydrochloric acid chlorine
After amine ketone (100mg/kg body weight) anesthesia, molding bay (lumbar vertebra center is on the upper side) shaving, with diameter 2cm plastic bottle closure at molding bay mark
Note modeling area, benzalkonium bromide tincture cotton balls skin degerming, cut off subcutaneous tissue to muscular fasciae, hemostasis, antiseptic gauze along mark line
Dressing covers wound, forms rat full skin injury opening wound model (general wound surface).In addition to general wound surface group, remaining 4
Group intramuscular injection hydrocortisone sodium succinate (8mg/100g body weight) at once after modeling, makes refractory wound surface model, notes continuously
Penetrate 5 days.Operation rose the same day, often organized equal intramuscular injection penicillin sodium salt (4000U/ is only), for three days on end, in case infecting.
1.5 medication
Each group starts to change dressings in modeling next day, and every day 1 time, all with 1/5000 nitrofural clean wound, general wound surface before changing dressings
Group and model control group all cover with normal saline gauze；Remaining is respectively organized respectively with vaseline, the embodiment of the present invention 5, removing the necrotic tissue
SHENGFU GAO spreads on wound surface, and external sterile gauze covers, and medical proof fabric is fixed, and changes dressings until all wound surface all heal.
1.6 observation index
1.6.1 Wound healing rate: after modeling the 5th, 7,10 days, uses transparent plastic mulching wound surface, mark stroke film, then by transparent
Film covers and calculates wound surface area on electrocardiograph paper.By following equation calculating Wound healing rate: healing rate=(original wound surface area-
Do not heal wound surface area)/original wound surface area × 100%.
1.6.2 wound healing time: record plays wound surface complete epithelization required time from topical agent.
1.7 statistical method
SPSS11.0 software is used to carry out data analysis.Continuous data mean ± standard deviation represents, carries out multiple sample Dan Yin
Group difference is compared in element variance analysis.
2 results
2.1 impacts on Wound healing rate
5th day, the 7th day, the 10th day model control group Wound healing rate be below general wound surface group (P ＜ 0.05), show to make
Mould success.5th day, each intervention group Wound healing rate compared no significant difference (P ＞ 0.05) with model control group；7th day, all
Intellectual circle's group, necrosis removing and granulation promoting plaster group healing rate are above model control group (P ＜ 0.05)；10th day, of the present invention group of healing rate was obvious
Higher than vaseline group, necrosis removing and granulation promoting plaster group (P ＜ 0.01).It is shown in Table 1.
Table 1 is respectively organized different time points Wound healing rate and is compared
| Group | n | 5th day | 7th day | 10th day |
| General wound surface group | 8 | 22.15±12.89 | 34.17±10.16 | 43.27±6.38 |
| Model control group | 8 | 22.88±4.10* | 39.56±6.19* | 55.37±6.48 |
| Vaseline group | 8 | 25.87±11.63 | 54.17±13.29Δ | 67.28±13.29 |
| Necrosis removing and granulation promoting plaster group | 8 | 29.17±12.19 | 47.38±12.27 | 63.91±10.27 |
| Of the present invention group | 8 | 35.17±11.27 | 68.26±13.26Δ | 90.32±13.29ΔΔ |
Compare with general wound surface group,*P ＜ 0.05；Compare with model control group,ΔP ＜ 0.05,ΔΔP ＜ 0.01.
2.2 impacts on wound healing time
Model control group wound healing time compared with normal wound surface group is obviously prolonged (P ＜ 0.01)；Compare with model control group, this
Bright powder group healing time shortens (P ＜ 0.01).It is shown in Table 2.
Table 2 is respectively organized wound healing time and is compared
| Group | n | Wound healing time | The average healing |
| General wound surface group | 8 | 16-20 | 18.98±1.48 |
| Model control group | 8 | 18-25 | 22.79±2.29** |
| Vaseline group | 8 | 17-22 | 19.78±2.17 |
| Necrosis removing and granulation promoting plaster group | 8 | 18-24 | 22.18±2.19 |
| Of the present invention group | 8 | 11-15 | 12.48±1.96ΔΔ |
Compare with general wound surface group,**P ＜ 0.01；Compare with model control group,ΔΔP ＜ 0.01.
Embodiment 9 clinical trial:
1 data and method
1.1 clinical data
1.1.1 all patients of diagnostic criteria all use the new diagnostic criteria of WHO diabetes in 1999, are diagnosed as type 2 diabetes mellitus also
Meet typing and the grade scale of diabetic foot.
1.1.2 diabetic foot (DF) ulcers 400 example, the maleest 203 examples, female 197 example, age 25～65 years old, the course of disease 2～
25 years, average (8.69 ± 2.03) year；Thoughtful 10 months of the diabetic foot course of disease 1, average (2.21 ± 0.39) individual month；Enter
Fasting glucose (I1.58 ± 2.16) mmol/L during institute.It is randomly divided into 8 groups, often organizes 50 examples, wherein treatment group totally five groups,
It is respectively treatment 1 group, treats 2 groups, treat 3 groups, treat 4 groups, treat 5 groups, use embodiment 1-5 medicine respectively,
Matched group totally 3 groups, is respectively comparison 1 group, compares 2 groups, compares 3 groups, uses comparative example 1-2 medicine, celebrating big respectively
Mycin, each group age of patient, sex, the course of disease and severity extent aspect comparing difference are without significance (P ＞ 0.05), and having can
Compare property.
1.2 Therapeutic Method
1.2.1 respectively to organize case identical for Experience of Combined Treatment of Internal Medicine.The most all control blood glucose in desirable level with oral antidiabetic drug or insulin；
2. effective antibiotic is selected to control to infect according to secretions antibacterial culturing and drug sensitive test；3. microcirculation and expansion are improved
Vascular treatment；4. reasonable diet, controls body weight；5. health education, advises appropriate exercise, notes the self health care of foot.
1.2.2 planing surface processes each group of case and all selects wound excision.First with ANER DIAN sterilization ulcer surrounding skin, wound surface has pus
Or the more person of secretions, clean with 3% hydrogen peroxide, then with the flushing of normal saline eddy current type, and with 0.1% hibitane cotton balls
Cleaning wound surface and removal slough.Finally alternately irrigate with 3% hydrogen peroxide+normal saline+metronidazole, finally with raw
Reason saline washes down wound surface, and is stained with dry with sterile gauze.
1.2.3 usage: skin ulcer face is first carried out with 3% hydrogen peroxide, wipes out slough as far as possible, then cleans with normal saline,
Surrounding skin 75% alcohol disinfecting, is then dispersed in skin ulcer face by the medicaments uniformity of embodiment of the present invention 1-5 or comparative example 1-2
On, it is advisable to surrounding normal skin to cover and to exceed whole skin ulcer face, then covers 2～3 layers of sterile gauze, use Breathable adhesive tape
Fixing, change dressings 1 day 1 time.Treat 20 days is 1 course for the treatment of.
Compare 3 groups and use gentamycin soak on the basis of conventional General Medicine treatment and debridement.Method: gentamycin 240,000 u
It is diluted in 50ml normal saline.Ulcer surface, enclosing cover 2～3 layers of sterile gauze are spread on, with ventilative after being soaked by sterile gauze
Immobilization with adhesive tape.Change dressings 1 day 1 time.Treat 20 days is 1 course for the treatment of.
The change of 1.3 observation index and method 1. ulcer surface, the character of secretions and color, whether incrustation comes off；2. treat
Front and back do that blood, urine, feces three are big conventional and hepatic and renal function inspection, have during observing and record treatment but erythra, local pain,
The untoward reaction such as dizzy, to feel sick occurs；3. all treatments of each group follow up a case by regular visits to 6 months after terminating.
1.4 statistical method measurement datas T checks, and ranked data rank test, all computings are all soft at SPSS13.0
Part is carried out.
2 results
2.1 efficacy assessment standards are cured: ulcer wound surface heals completely, Wagner classification 0 grade；Take a turn for the better: ulcer wound surface reduces,
Secretions reduces, and clinical Wagner classification takes a turn for the better more than 1 rank；Invalid: ulcer wound surface is without reducing, and secretions is without subtracting
Few, clinical scale is without taking a turn for the better or deteriorating.
2.2 respectively group comprehensive therapeutic effects compare and be shown in Table 3.Comparing on cure rate and total effective rate, observation group is substantially better than matched group,
There is statistical significance (p ＜ 0.05).
Table 3 is respectively organized comprehensive therapeutic effect and is compared [example]
| Group | Total number of cases | Recovery from illness | Take a turn for the better | Invalid | Total effective rate % | Recur after healing |
| Treat 1 group | 50 | 40 | 8 | 2 | 96 | 0 |
| Treat 2 groups | 50 | 41 | 8 | 1 | 98 | 0 |
| Treat 3 groups | 50 | 45 | 5 | 0 | 100 | 0 |
| Treat 4 groups | 50 | 46 | 4 | 0 | 100 | 0 |
| Treat 5 groups | 50 | 50 | 0 | 0 | 100 | 0 |
| Compare 1 group | 50 | 1 | 17 | 32 | 36 | 1 |
| Compare 2 groups | 50 | 0 | 3 | 47 | 6 | 0 |
| Compare 3 groups | 50 | 34 | 5 | 11 | 78 | 4 |
As can be known from Table 3, the therapeutic effect of embodiment of the present invention 1-5 is better than compareing 1-3 group.The healing of the medicine of the present invention
Rate more than 80%, total effective rate more than 96%, and non-relapse after healing, preferably embodiment 3-5, cure rate 90% with
On, total effective rate 100%, optimum is embodiment 5, and 100% cures；Although the total effective rate compareing 3 groups is high, but its
Cure rate is the highest, is 68%, and controlling recurrence rate after healing is 11.8%.Over the course for the treatment of, Chinese medicine composition of the present invention does not finds
Any toxicity, side effect.Treat 5 groups compared with comparison 1-2 group, it can be seen that the present invention is the common work in each component
By lower effect.
Model case
Zhang, man, 62 years old, diabetic history 20 years, sky takes blood glucose 14mnol/l, urine examination ++, left lower extremity ulcer gangrene 3
Year, numb around ulcer, to feel to go down, have hospital to advise amputation, oral administration hypoglycemic medicine, glycemic control is at 6.5mnol/l
Left and right, uses the present invention afterwards, locally after debridement, the present invention is coated on wound surface, within 1st, changes dressings once, wound surface purulent secretion
Significantly reduce, wound surface incrustation, wound healing after 20 days after 14 days, follow up a case by regular visits to without recurrence.
It is obvious to a person skilled in the art that the invention is not restricted to the details of above-mentioned one exemplary embodiment, and do not carrying on the back
In the case of the spirit or essential attributes of the present invention, it is possible to realize the present invention in other specific forms.Therefore, no matter from
From the point of view of which point, all should regard embodiment as exemplary, and be nonrestrictive, the scope of the present invention is by appended power
Profit requires rather than described above limits, it is intended that all by fall in the implication of equivalency and scope of claim
Change is included in the present invention.
Although moreover, it will be appreciated that this specification is been described by according to embodiment, but the most each embodiment only comprises
One independent technical scheme, this narrating mode of description is only the most for clarity sake, and those skilled in the art should be by
Description is as an entirety, and the technical scheme in each embodiment can also be through appropriately combined, and forming those skilled in the art can
With other embodiments understood.
Claims (5)
1. the preparation treating diabetic foot chronic ulcer, it is characterised in that be made up of according to the raw material of weight portion following:
Canis familiaris L. ant grass 10-18 part, Rhizoma Chiritae Fimbrisepalae 22-30 part, Herba Galii Bungei 15-23 part, Radix et Rhizoma Dysosmatis 2-8 part.
The preparation for the treatment of diabetic foot chronic ulcer the most according to claim 1, it is characterised in that by following according to weight
The raw material composition of amount part: Canis familiaris L. ant grass 12-16 part, Rhizoma Chiritae Fimbrisepalae 24-28 part, Herba Galii Bungei 17-21 part, Radix et Rhizoma Dysosmatis 4-6 part.
The preparation for the treatment of diabetic foot chronic ulcer the most according to claim 2, it is characterised in that by following according to weight
The raw material composition of amount part: Canis familiaris L. ant grass 14 parts, Rhizoma Chiritae Fimbrisepalae 26 parts, Herba Galii Bungei 19 parts, Radix et Rhizoma Dysosmatis 5 parts.
4. a preparation method for the preparation of the treatment diabetic foot chronic ulcer as described in claim 1-3 is arbitrary, its feature
It is, comprises the steps of:
1) Canis familiaris L. ant grass, Rhizoma Chiritae Fimbrisepalae are pulverized 100-150 mesh sieve, add 75% ethanol solution of the two quality 8-10 times,
Under the High Temperature High Pressure of 4-5MPa, 100-120 DEG C, process 1-1.3h, take filtrate after filtration and prepare mixed liquor A；
2) Herba Galii Bungei pulverized, cross 200 mesh sieves, add the deionized water of its quality 13-15 times, add at 110-115 DEG C
Hot 1.5-2h, crosses leaching filtrate, prepares mixture B；
3) Radix et Rhizoma Dysosmatis was pulverized 60 mesh sieves, and added and fry at the vinegar of its quality 0.5-0.8 times, then 75-80 DEG C
15-20min processed, more ground 200 mesh sieves, prepare Radix et Rhizoma Dysosmatis powder；
4) mixture A is mixed with mixture B, then heated and stirred 15-20min at 140-150 DEG C, then it is down to 70-75
DEG C, add Radix et Rhizoma Dysosmatis powder, at such a temperature heated and stirred 30-35min, be down to room temperature and i.e. obtain preparation.
5. the application in preparation treatment diabetic foot chronic ulcer medicine of the preparation as described in claim 1-3 is arbitrary.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610235298.3A CN105726702A (en) | 2016-04-11 | 2016-04-11 | Preparation for treating chronic diabetic foot ulcers and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610235298.3A CN105726702A (en) | 2016-04-11 | 2016-04-11 | Preparation for treating chronic diabetic foot ulcers and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105726702A true CN105726702A (en) | 2016-07-06 |
Family
ID=56255646
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610235298.3A Pending CN105726702A (en) | 2016-04-11 | 2016-04-11 | Preparation for treating chronic diabetic foot ulcers and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105726702A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106448105A (en) * | 2016-09-29 | 2017-02-22 | 安徽翼讯飞行安全技术有限公司 | Fixed-point pesticide spraying unmanned plane |
-
2016
- 2016-04-11 CN CN201610235298.3A patent/CN105726702A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106448105A (en) * | 2016-09-29 | 2017-02-22 | 安徽翼讯飞行安全技术有限公司 | Fixed-point pesticide spraying unmanned plane |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1326546C (en) | Pure Chinese medicinal preparation for external treating burn and scald | |
| CN103340965A (en) | External pharmaceutical composition used for treating skin diseases like eczema, dermatitis and tinea and preparation method thereof | |
| JP2009269904A (en) | Herbal medicinal composition for curing external wound and bedsore and method of manufacturing medicine from the composition | |
| CN108578478A (en) | The Lonicera and Forsythia cream and preparation method thereof massaged for children's wind-heat cold | |
| CN102872335B (en) | Externally used Chinese medicine preparation for curing diabetic foot and preparation method thereof | |
| CN102631464B (en) | Chinese medicinal ointment for treating infantile hemangioma and preparation method thereof | |
| CN107582935A (en) | A kind of lavipeditum pack for treating the ringworm of the foot | |
| CN105726702A (en) | Preparation for treating chronic diabetic foot ulcers and preparation method and application thereof | |
| CN104306402B (en) | A kind of Chinese medicine composition for treating burn and scald infection and preparation method thereof | |
| CN103721138B (en) | A kind of traditional Chinese medicine for external application and its preparation method treating rosacea | |
| CN100386106C (en) | Medicine for treating acne and its preparation | |
| CN105213584A (en) | A kind of Chinese medicine composition for the treatment of eczema and preparation method thereof | |
| CN109662999A (en) | A kind of pulvis and preparation method thereof for treating diabetic foot ulcer | |
| CN114886979A (en) | Medicine for treating skin disease and its preparing method | |
| CN103751342B (en) | A kind of medicine with heat-clearing and toxic substances removing, reducing swelling and alleviating pain function | |
| CN102755414A (en) | Traditional Chinese medicine ointment for trauma wound and preparation method thereof | |
| CN100369612C (en) | External-use powder medicine for wetting burn and empyrosis and its preparing method | |
| CN109260426A (en) | A kind of disease eliminating powder junction pain-stopping external use Chinese medicine and its preparation method and application | |
| CN109395050A (en) | Paediatrics external application massage the ointment formula, preparation method and application for treating diarrhea | |
| CN108379327A (en) | A kind of anaesthetic and its preparation process for treating nose-nasosinusitis | |
| CN1406591A (en) | Medicine against aseptic inflammation by ranunculaceae plant and use thereof | |
| CN103156900B (en) | Safflower medicine aerosol and preparation method thereof | |
| CN1259079C (en) | Osteopathy treating ointment | |
| CN111939203B (en) | Traditional Chinese medicine ointment preparation for treating diabetic foot and preparation method thereof | |
| CN102526413B (en) | Bladder care irrigation solution and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160706 |
|
| WD01 | Invention patent application deemed withdrawn after publication |